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A B S T R A C T
Heart failure still remains the main cause of death in β-thalassemia, despite the prog-
ress, which was made by intensification of iron chelation therapy. Iron myocardial 
deposition, due to regular blood transfusions, can cause congestive heart failure as 
a result of left- or right-sided heart failure combined with left ventricular myocardial 
restriction. Regular and intense chelation therapy has improved quality of life and 
survival by decreasing secondary hemochromatosis. However, heart failure has not 
been prevented despite the intensification of iron chelation therapy.
Acute myocarditis in β-thalassemia major has been reported to contribute to heart 
failure in addition to iron overloading. However, apart from myocarditis which may 
lead to immune mediated chronic left ventricular dysfunction and failure, other fac-
tors acting through immunologic or genetically defined mechanisms might also affect 
the development of left sided heart failure. Multiple transfusions represent a repeti-
tive antigenic stimulus together with iron chelation therapy itself. In this brief over-
view, the pathogenetic mechanisms of myocardial involvement and heart failure in 
β-thalassemia major are discussed.
β - T h A l A S S e m i A ,  m y o C A R d i A l  i R o n  
A n d  C o n g e S T i v e  h e A R T  F A i l u R e
Iron myocardial deposition can cause congestive heart failure as a result of left- or 
right-sided heart failure combined with left ventricular myocardial restriction. Heart 
failure still remains the main cause of death in β-thalassemia, despite the progress, 
which was made by intensification of iron chelation therapy.1,2 It is traditionally con-
sidered the result of iron overload due to regular blood transfusions, iron intestinal 
hyperabsorption and ineffective erythropoiesis during the life span of the patients.3,4 
Regular and intense chelation therapy has improved quality of life and survival by 
decreasing the patients’ secondary hemochromatosis. However, heart failure has not 
been prevented despite the intensification of iron chelation therapy.5,6 It can thus be 
hypothesized that either deferoxamine is less effective than it is believed or other fac-
tors might be involved in the pathogenesis of heart failure.
β-thalassemia is not a pure iron storage disease and the pathophysiology of car-
diac dysfunction is poorly understood and multifactorial in etiology.7,8 Left-sided and 
subsequently biventricular heart failure appears early in the patients’ life. This is the 
commonest mode of heart failure in this disease characterized at diagnosis by left 
ventricular systolic dysfunction, dilatation and failure.3,9-11
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m y o C A R d i A l  R e S T R i C T i o n
Chronic iron myocardial deposition does not affect left 
ventricular relaxation but causes left ventricular myocardial 
restriction with highly elevated pulmonary arteriolar resist-
ance and pressure. It appears in the elderly β-thalassemia 
major population with the highest serum ferritin levels. The 
patients eventually develop right ventricular dilatation while 
left ventricular dimensions and systolic function remain within 
normal range. This is the pre-stage of heart failure with pre-
dominant symptoms and signs of right-sided heart failure.12
m y o C A R d i T i S
Engle et al in 1964 first reported the co-existence of 
pericarditis and fatal arrhythmias with heart failure in β-tha-
lassemia major. Of note, pericarditis usually coincides to some 
degree with myocarditis being a part of inflammatory heart 
disease which has usually an immunological background.3,13,14 
years later we proved15 that acute infectious myocarditis 
in β-thalassemia major apart from acute can also cause a 
chronic left-sided heart failure in 27.6% of myocarditis patients 
within 3.5 years approximately, compared to β-thalassemic 
population aged and sex-matched with no difference in iron 
loading. The estimated prevalence of overt myocarditis in 
β-thalassemia was 4.5% in a population with clinical evi-
dence of myopericarditis documented mainly by myocardial 
biopsy. However, the exact significance of acute myocarditis 
as a contributing factor for heart failure development is not 
easy to be defined since there is a possibility of existence 
of latent undiagnosed myocarditis in unknown percentage 
of β-thalassemia major population. Myocarditis can cause 
acute or chronic left ventricular systolic dysfunction and 
dilatation analogous to dilated cardiomyopathy which appear 
to be mediated by predominantly immunologic mechanisms 
rather than viral infection and replication.16,17 The increased 
frequency of infections associated with β -thalassemia seems 
to be related to abnormalities of the immune system.18,19 The 
predisposition to autoimmune diseases is under the control 
of immune response genes, which play a central role in the 
presentation of antigens to the immune system.20 In dilated 
cardiomyopathy, immune related disorders show preferential 
associations with HLA genes.21 In β-thalassemia major left 
ventricular dysfunction attributed to myocarditis seems to 
be related to immune system dysregulation being under im-
munogenetic control. HLA-DRB1* 1401 allele frequency was 
found significantly increased in patients with β-thalassemia 
major without left sided heart failure compared with those with 
heart failure and healthy controls. HLA-DQA1*0501 allele 
frequency was also significantly increased in β-thalassemic 
patients with heart failure compared with patients without 
heart failure and healthy controls. HLA-DRB1*1401 allele 
might have a protective effect in the pathogenesis of heart 
failure, while HLA-DQA1*0501 allele is possibly related to 
an increased risk for heart failure development.22
i m m u n o g e n e T i C  R i S K  FA C T o R S
Apart from myocarditis which may lead to immune medi-
ated chronic left ventricular dysfunction and failure, other 
factors acting through immunologic or genetically defined 
mechanisms might also affect the development of left sided 
heart failure. Multiple transfusions represent a repetitive anti-
genic stimulus together with iron chelation therapy itself. This 
is supported by the increased IgA neutral antibody activity 
found in the sera of patients with homozygous β-thalassemia 
major.23 Iron loading apart from its toxic effect might contrib-
ute to heart failure development through immune mediated 
mechanisms.24 The exact mechanism of iron overload toxicity 
has been uncertain for many years. Via the iron-driven Fenton 
and Haber-Weiss reactions, the nontransferrin plasma iron in 
its bivalent or trivalent form has a high toxicity through the 
formation of hydroxy radicals (OH).25 Imbalance between 
production of oxygen free radicals and antioxidant defense 
mechanisms can result in oxidative stress and human dis-
ease.26 In the heart, the imbalance between free radicals and 
antioxidant mechanisms is manifested as impaired function of 
the mitochondrial inner membrane respiratory chain, result-
ing in abnormal energy metabolism expressed clinically with 
dilated cardiomyopathy, which is also observed in patients with 
acute myocarditis in the acute or chronic phase. As shown in 
animal models, oxygen free radicals may also contribute to 
the pathogenesis of infectious myocarditis.27,28
In homozygous β-thalassemia, organ damage is mainly at-
tributed to excessive iron deposition through the formation of 
free radicals. β-thalassemia major patients without left sided 
heart failure have an apolipoprotein Eε4 allele frequency 
similar to that of healthy controls, while patients with left sided 
heart failure have a higher frequency of this allele relative 
to controls.29 The apolipoprotein Eε4 allele may represent a 
genetic risk factor for the development of heart failure through 
the mechanisms of free radicals, which are related either with 
iron toxicity or acute infectious myocarditis. Thus, despite that 
it is conventionally believed that cardiac involvement leads to 
a mixed dilated/restrictive cardiomyopathy with both systolic 
and diastolic dysfunction,30 recent studies showed that left 
ventricular dysfunction and failure is related to a multifactorial 
etiology.7 It seems that apart from iron loading, immunogenetic 
risk factors trigger the mechanisms of left sided heart failure 
development, on the basis of dilated type cardiomyopathy.
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